Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
The Patients Deserve Price Tags Act amends the Public Health Service Act, ERISA, the Internal Revenue Code, and related statutes to expand and strengthen health care price-transparency and data-access rules across hospitals, clinical laboratories, imaging providers, ambulatory surgical centers, health plans, and health-plan service providers. Key provisions require machine‑readable and consumer‑friendly public posting of gross charges, discounted cash prices, payer‑specific negotiated rates, and de‑identified min/max negotiated prices; require attestations from senior officials; mandate audits and corrective action processes; and authorize civil monetary penalties for noncompliance.
Scope and intrusiveness of required disclosures: liberals emphasize consumer benefits, conservatives emphasize protection of proprietary contract terms.
Relative to its intended legislative type, this bill is a comprehensive, detailed substantive policy change that clearly defines new mandatory disclosure obligations, formats, enforcement steps, and definitions across multiple sectors (hospitals, labs, imaging suppliers, ambulatory surgical centers, insurers, and plan service providers).
The Patients Deserve Price Tags Act amends the Public Health Service Act, ERISA, the Internal Revenue Code, and related statutes to expand and strengthen health care price-transparency and data-access rules across hospitals, clinical laboratories, imaging providers, ambulatory surgical centers, health plans, and health-plan service providers.
Key provisions require machine‑readable and consumer‑friendly public posting of gross charges, discounted cash prices, payer‑specific negotiated rates, and de‑identified min/max negotiated prices; require attestations from senior officials; mandate audits and corrective action processes; and authorize civil monetary penalties for noncompliance.
The bill also requires detailed explanation-of-benefits notices within 45 days of payment requests, itemized patient bills prior to collections, prohibits contract terms that limit plan access to claims and pricing data, and imposes disclosure obligations and stiff penalties on third-party administrators, PBMs, and other plan service providers.
Judged solely on content and historical legislative patterns, this is a substantial regulatory package that addresses a widely recognized problem (opaque health prices) but imposes heavy operational burdens and stiff penalties across multiple powerful industries. Those factors typically trigger prolonged negotiation, industry lobbying, possible legal challenges, and stepwise or broken-up adoption (piecemeal provisions or narrower bills are more common). The bill contains some phased implementation and technical-assistance features that improve plausibility, but overall its breadth and enforcement provisions reduce the standalone chance of enactment without significant amendment or incorporation into a larger legislative vehicle.
Relative to its intended legislative type, this bill is a comprehensive, detailed substantive policy change that clearly defines new mandatory disclosure obligations, formats, enforcement steps, and definitions across multiple sectors (hospitals, labs, imaging suppliers, ambulatory surgical centers, insurers, and plan service providers). It incorporates many accountability features and integrates tightly with existing statutory frameworks.
Scope and intrusiveness of required disclosures: liberals emphasize consumer benefits, conservatives emphasize protection of proprietary contract terms.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and intrusiveness of required disclosures: liberals emphasize consumer benefits, conservatives emphasize protection of proprietary contract terms.
A mainstream progressive would likely view this bill largely favorably because it expands consumer access to pricing information, limits surprise bills, increases accountability for hospitals and intermediaries, and restricts gag clauses that have hidden costs from patients and plans.
They would see the required public posting of payer‑specific negotiated rates, acceptance of discounted cash prices, attestation requirements, and strict penalties as tools to expose opaque pricing and strengthen oversight.
They may be cautious that transparency alone may not lower prices without additional measures, and may press for strong enforcement, accessible consumer tools, and protections for low‑income patients.
A pragmatic moderate would generally support the bill's goals of improving price transparency and strengthening plan access to data, while being mindful of implementation complexity, administrative burden, and costs.
They would value requirements for machine‑readable files, attestation, and limits on gag clauses as improvements to market functioning and fiduciary oversight, but want careful, measured rulemaking and phased compliance to avoid disrupting care delivery or imposing disproportionate costs on small providers.
They would focus on ensuring data accuracy, consumer usability, privacy protections, and reasonable penalty structures tied to demonstrated willful noncompliance.
A mainstream conservative would likely oppose much of the bill as an expansive federal regulatory intervention that imposes heavy disclosure mandates and steep penalties on health providers, intermediaries, and plan service vendors.
They would be especially concerned about federal overreach into private contracts, disclosure of negotiated rates and contract formulas (seen as proprietary), the high per‑day and aggregate penalties (including $100,000/day for service provider violations), and new administrative burdens on hospitals and small providers.
They would worry the rules could disrupt negotiated networks, harm rural hospitals, increase compliance costs that flow to patients, and interfere with private‑sector negotiation.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Judged solely on content and historical legislative patterns, this is a substantial regulatory package that addresses a widely recognized problem (opaque health prices) but imposes heavy operational burdens and stiff penalties across multiple powerful industries. Those factors typically trigger prolonged negotiation, industry lobbying, possible legal challenges, and stepwise or broken-up adoption (piecemeal provisions or narrower bills are more common). The bill contains some phased implementation and technical-assistance features that improve plausibility, but overall its breadth and enforcement provisions reduce the standalone chance of enactment without significant amendment or incorporation into a larger legislative vehicle.
The bill has not accumulated any surfaced votes yet.
Scope and intrusiveness of required disclosures: liberals emphasize consumer benefits, conservatives emphasize protection of proprietary co…
Judged solely on content and historical legislative patterns, this is a substantial regulatory package that addresses a widely recognized p…
Relative to its intended legislative type, this bill is a comprehensive, detailed substantive policy change that clearly defines new mandatory disclosure obligations, formats, enforcement steps, and definitions across m…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.